Evidence map›Paper›PMID 31175581›Full record

SynthesisHepatology international2019

Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis.

Xiangbo Xu, Xiaozhong Guo, Valerio De Stefano, Gilberto Silva-Junior, Hemant Goyal, Zhaohui Bai, Qingchun Zhao, Xingshun Qi

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Hepatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Portal Vein Thrombosis Risk in Cirrhotic Patients With Portal Hypertension on Beta-Blockers: A Multi-Institutional Cohort Study.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. [New targets for the prevention and treatment of cirrhotic portal vein thrombosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Review
  15. Management of Nonmalignant Portal Vein Thrombosis in Cirrhosis.GE Portuguese journal of gastroenterology · 2024
    Review
  16. Management of splanchnic vein thrombosis.JHEP reports : innovation in hepatology · 2023
    Review
  17. [Exploration of pathogenesis and clinical diagnosis and treatment for portal vein thrombosis formation].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Article
  18. Article
  19. [New recognition of portal vein thrombosis mechanism and treatment in cirrhosis].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Xiangbo XuLiver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly Called General Hospital of Shenyang Military Area), No. 83 Wenhua Road, Shenyang, 110840, Liaoning, China.
Xiaozhong GuoLiver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly Called General Hospital of Shenyang Military Area), No. 83 Wenhua Road, Shenyang, 110840, Liaoning, China.
Valerio De StefanoFondazione Policlinico A. Gemelli IRCCS, Istituto Di Ematologia, Università Cattolica, Rome, Italy.
Gilberto Silva-JuniorDepartment of General Medicine and Hepatology, Quinta D'Or Hospital, Rio de Janeiro, Brazil.
Hemant GoyalDepartment of Internal Medicine, School of Medicine, Mercer University, Macon, GA, USA.
Zhaohui BaiLiver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly Called General Hospital of Shenyang Military Area), No. 83 Wenhua Road, Shenyang, 110840, Liaoning, China.
Qingchun ZhaoPostgraduate College, Shenyang Pharmaceutical University, Shenyang, China.
Xingshun QiLiver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (Formerly Called General Hospital of Shenyang Military Area), No. 83 Wenhua Road, Shenyang, 110840, Liaoning, China. xingshunqi@126.com.ORCID http://orcid.org/0000-0002-9448-6739
Shenyang Pharmaceutical University · CNGeneral Hospital of Shenyang Military Region · CNAgostino Gemelli University Polyclinic · ITD’Or Institute for Research and Education · BRMercer University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Portal vein thrombosis (PVT), which is associated with reduced portal vein velocity, is considered to be an indicator for worse outcomes in liver cirrhosis. Nonselective beta-blockers (NSBBs), which are widely used for primary and secondary prophylaxis of esophageal variceal bleeding in liver cirrhosis, can significantly decrease the portal vein velocity. We proposed a hypothesis that the use of NSBBs might facilitate the development of PVT in cirrhotic patients. The PubMed, EMBASE, and Cochrane Library databases were searched. Major meeting abstracts and randomized-controlled trials regarding the use of NSBBs in liver cirrhosis were also hand-searched. The number of patients who developed PVT in groups treated with or without NSBBs was pooled. Odds ratios (ORs) or risk ratios (RRs) with 95% confidence intervals (CIs) were calculated. Subgroup meta-analyses were performed according to the type of studies, region, and study quality. Meta-regression and sensitivity analyses were performed to explore the source of heterogeneity. Nine of the 6416 retrieved papers were finally included. Overall, meta-analysis demonstrated that NSBBs were significantly associated with the development of PVT (OR 4.62, 95% CI 2.50-8.53; p < 0.00001). The heterogeneity was statistically significant (I

Indexed as

Portal VeinAdrenergic beta-AntagonistsAdultEpidemiologic MethodsEsophageal and Gastric VaricesFemaleGastrointestinal HemorrhageHumansLiver CirrhosisMalePrognosisVenous ThrombosisAdrenergic beta-AntagonistsLiver cirrhosisNonselective beta-blockersPortal hypertensionPortal vein thrombosisPropranolol

Identifiers

PMID31175581
OpenAlexW2948576133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.